Carolyn Magill, Aetion CEO (via YouTube)

Ae­tion push­es Se­ries B to $82M as pan­dem­ic puts re­al-world ev­i­dence un­der the spot­light

For­mer FDA chief Scott Got­tlieb’s fa­vorite re­al-world ev­i­dence plat­form is get­ting a new stream of cash, as it nears what will like­ly be the biggest test of the young com­pa­ny so far.

Ae­tion, the New York health tech start­up, has for the sec­ond time raised an ex­ten­sion to their Se­ries B, adding $19 mil­lion from J&J’s VC arm, Green­spring As­so­ciates and ED­BI to bring their round to $82 mil­lion. Got­tlieb, who cham­pi­oned re­al-world ev­i­dence as com­mis­sion­er and lat­er joined the com­pa­ny’s board, said in a state­ment that the new cash would help fu­el a glob­al ex­pan­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.